Overview about Candida auris: what's up 12 years after its first description? - Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 Access content directly
Journal Articles Journal of Medical Mycology = Journal de Mycologie Médicale Year : 2022

Overview about Candida auris: what's up 12 years after its first description?

Abstract

Candida auris has been described as an emerging yeast species during the last decade. As many as 25% of its strains may naturally exhibit multi-drug resistance to the currently available antifungal drugs. Probably due to its ability to survive more than two weeks on inert surfaces, several large outbreaks have been reported, primarily due to nosocomial transmissions. In addition, due to a rapid worldwide spreading, C. auris is now considered as a major public health threat. This review aims at describing the current knowledge about C. auris, with specific focuses on its global epidemiology, virulence features, most reliable diagnostic approaches, and the current and future therapeutic options.
Fichier principal
Vignette du fichier
Desoubeaux et al. - 2022 - Overview about Candida auris What's up 12 years a.pdf (784.38 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03554923 , version 1 (03-02-2022)

Identifiers

Cite

Guillaume Desoubeaux, Alix T Coste, Christine Imbert, Christophe Hennequin. Overview about Candida auris: what's up 12 years after its first description?. Journal of Medical Mycology = Journal de Mycologie Médicale, 2022, 32 (2), pp.101248. ⟨10.1016/j.mycmed.2022.101248⟩. ⟨hal-03554923⟩
121 View
142 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More